Invention Title:

METHOD AND SYSTEM FOR THE TRANSDERMAL ADMINISTRATION OF A PSYCHEDELIC AGENT

Publication number:

US20240358783

Publication date:

2024-10-31

Section:

Human necessities

Class:

A61K36/185

Inventors:

Frank Kochinke San Jose, CA, United States

Chad CONNER San Diego, CA, United States

Bryan ARRAYALES Los Angeles, CA, United States

Applicant:

LYFE CHNG, LLC South Lake Tahoe, CA, United States

Drawings (4 of 9)

Drawing 01 for METHOD AND SYSTEM FOR THE TRANSDERMAL ADMINISTRATION OF A PSYCHEDELIC AGENT

Drawing 02 for METHOD AND SYSTEM FOR THE TRANSDERMAL ADMINISTRATION OF A PSYCHEDELIC AGENT

Drawing 03 for METHOD AND SYSTEM FOR THE TRANSDERMAL ADMINISTRATION OF A PSYCHEDELIC AGENT

Drawing 04 for METHOD AND SYSTEM FOR THE TRANSDERMAL ADMINISTRATION OF A PSYCHEDELIC AGENT

Smart overview of the Invention

The patent application introduces a method and system for transdermal administration of psychedelic agents, specifically focusing on psilocin. This approach aims to maintain continuous microdose plasma levels over an extended period, addressing the limitations of oral and intravenous administration. The system includes a drug reservoir with a formulation that combines solubilizer and plasticizer-type permeation enhancers, alongside a pH stabilizing agent.

Technical Field

This invention relates to the field of pharmacotherapy, specifically using psychedelic agents for treating various disorders. The focus is on transdermal delivery of these agents to prevent and treat conditions while minimizing adverse effects associated with traditional administration methods.

Background

Research on psychedelic agents like psilocybin has increased, revealing potential therapeutic benefits for mental health conditions. Psilocybin, found in Psilocybe mushrooms, is a prodrug that converts to psilocin, its active form. Oral or intravenous administration can lead to unpredictable effects due to individual metabolic differences and can cause adverse events like gastrointestinal distress and psychological reactions.

Challenges and Solutions

The primary challenge with psilocybin is its inability to cross the blood-brain barrier due to its zwitterionic nature. Moreover, transdermal delivery has been traditionally challenging for charged molecules. However, this invention demonstrates that psilocin can effectively penetrate the skin's stratum corneum and upper layers, making it suitable for transdermal delivery.

Significance

This transdermal system offers a promising alternative for administering psychedelic agents by bypassing gastrointestinal side effects and reducing psychological risks associated with higher doses. It provides a controlled release mechanism that could enhance patient safety and therapeutic efficacy in treating various mental health disorders.